Theranexus Société Anonyme (EPA:ALTHX)

France flag France · Delayed Price · Currency is EUR
2.520
-0.050 (-1.95%)
Sep 4, 2025, 1:38 PM CET
-1.95%
Market Cap21.94M
Revenue (ttm)2.28M
Net Income (ttm)-1.77M
Shares Out8.54M
EPS (ttm)-0.21
PE Ration/a
Forward PE5.81
Dividendn/a
Ex-Dividend Daten/a
Volume12,716
Average Volume268,968
Open2.550
Previous Close2.570
Day's Range2.490 - 2.570
52-Week Range0.261 - 3.660
Beta1.83
RSI55.44
Earnings DateSep 25, 2025

About EPA:ALTHX

Theranexus Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was founded in 2013 and is headquartered in Lyon, France. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 10
Stock Exchange Euronext Paris
Ticker Symbol ALTHX
Full Company Profile

Financial Performance

In 2024, EPA:ALTHX's revenue was 2.28 million, an increase of 670.55% compared to the previous year's 296,331. Losses were -1.77 million, -74.15% less than in 2023.

Financial Statements

News

There is no news available yet.